___

• Bressler NM, Bressler SB, Fine SL . Age- related Ophthalmol, 1988; 32: 75–413.
• Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology,1995; 102: 1450–1460.
• Challa JK, Gillies MC, Penfold PL, et al. Exudative intravitreal triamcinolone: 18 month follow up. Aust NZJ Ophthalmol, 1998; 26: 277– 281.
• Penfold PL, Gyory JF, Hunyor AB, et al. Exudative intravitreal triamcinolone. A pilot study. Aust. NZ. J. Ophthalmol, 1995;23: 293–298. 5-Jonas JB
• Akkoyun I, Budde WM, et al. Intravitreal re-injection oftriamcinolone for exudative agerelated macular degeneration. Arch. Ophthalmol, 2004; 122: 218–222.
• Haddad WM, Souied E, Coscas G. Treatmentof exudative AMD with chorioretinal anastomosis
• photodynamic therapy with and without intravitreal injection of triamcinolone acetonide. ARVO-Abstracts, 2004; 3163/B: 798-799
• Bresnick GH. Diabetic retinopathy: a critical review highlighting diffuse macular edema. Ophthalmology, 1983; 90: 1301–1317.
• Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology, 1991; 98: 1594–1602.
• Degenring RF, Jonas JB. Serum levels of triamcinolone injection. Am. J. Ophthalmol, 2004; 137: 1142– 1143.
• Yıldırım Y, Ayata A, Ünal M. The effect of intravitreal triamcinolone acetonide on chronic diffuse diabetic macular edema resistant to conventional treatment. Retina Vitreus, 2005; 13,4:261-266
• Karacorlu M, Ozdemir H, Karacorlu S, et al. Regression neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression neovascularization triamcinolone. Int. Ophthalmol, 2004; 25: 113– 116.
• Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am. J. Ophthalmol,2004; 137: 1151–1153.
• Chen SD, Lochhead J, Patel CK, et al. Intravitreal ischaemic macular oedema caused by branch retinal vein occlusion. Br. J. Ophthalmol, 2004; 88: 154–155.
• Karaçorlu SA, Karaçorlu M, Özdemir H. The evaluation of macular changes after intravitreal triamcinolone acetonide in branch retinal vein occlusion. Retina Vitreus, 2005; 13,4: 273-277
• Çekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina, 2005; 25: 851-855
• Hayreh SS, Klugman MR, Podhajsky P, et al. Argon laser panretinal photocoagulation in ischemic pressure after intravitreal triamcinolone acetodine injection.Am. J. Ophthalmol, 1990;138: 286-287.
• Çekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina, 2005; 25:846-850
• Williamson TH, O’Donnell A. İntravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusıon. Am. J. Ophthalmol, 2005; 139 (5):860-866
• Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol, 2004; 122: 1131–1136
• Jonas JB, Kreissig I, Degenring RF. Repeated triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graef. Arch. Clin. Exp. Ophthalmol, 2002; 240: 873–874.
• Jonas JB, Söfker A, Degenring RF. Intravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur. J Ophthalmol, 2003;13: 468–473.
• Karacorlu M., Mudun B., Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am. J. Ophthalmol, 2004; 138: 289–291.
• Pathengay A. Intravitreal triamcinolone in serpiginous Ophtalmol, 2005; 53: 77-79
• Ünal M, Ayata A, Yıldırım Y. İntravitreal triamcinolone asetonide for treatment of sympathetic ophthalmia. Retina Vitreus, 2005; 13,4:311-314
• Jonas JB. Intravitreal triamcinolone acetonide as treatment of chronic focal immunologic corneal graft reaction. Graef. Arch. Clin. Exp. Ophthalmol, 2003; 241: 779–780.
• Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty. A pilot study. Transplant International. I. Transplant Int, 2002; 15: 81–88.
• Jonas JB, Kamppeter B. İntravitreal triamcinolone acetodine for persisting cystoid macular edema after penetrating keratoplasty. Cornea, 2006; 25 (2): 240-241
• Jonas JB, Hayler JK, Söfker A, et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J. Glaucoma, 2001; 10: 284–287
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina, 2003; 23: 113–116.
• Jonas JB, Harley JK, Panda-Jonas S. Intravitreal injection of crytalline cortisone as treatment of pre-phthisical ocular hypotony. Graef. Arch. Clin. Exp. Ophthalmol, 2001; 239: 464-465
• Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive vitreoretinopathy. Br. J. Ophthalmol, 2001; 84: 1064–1067.
• Enaida H, Hata Y, Ueno A, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina, 2003; 23: 764–770.
• Jonas JB, Sofker A, Degenring RF. İntravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur. J. Ophthalmol, 2003; 13: 468-473.
• MunirWM, Pulido JS, Sharma MC. İntravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Canadian Journal of Ophthalmology, 2005; 40 (5): 598- 604 35-Kimura
• Triamcinolone acetonide assisted peeling of the internal limiting membrane. Am. J. Ophthalmol, 2004; 137: 172–173.
• Yamamoto N, Ozaki N, Murakami K. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica, 2004; 218: 248–256.
• Jonas JB, Kreissig I, Budde WM. Cataract surgery combined with intravitreal injection of triamcinolone acetonide. Eur. J. Ophthalmol, 2005; 15(3): 329-353
• Habib MS, Cannon PS, Steel DHW. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabetic foveal edema and cataract. B.M.C Ophthalmol, 2005; 5: 15-21
• Yamakiri K, Uchino E, Kimura K, et al. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am. J. Ophthalmol, 2004; 138: 650–652.
• Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection oftriamcinolone acetonide. Eye, 2004; 18: 361–364. 41-Jonas
• triamcinolone acetonide for cataract surgery with iris neovascularisation. J. Cataract. Refract. Surg, 2002; 28: 2040–2041.
• Jonas JB, Degenring RF, Kreissig I, et al. Intraocular intravitreal triamcinolone acetonide injection. Ophthalmology, 2005; 112: 593-598
• Civerchia LL, Balent A. Treatment of pseudophakic cystoid macular edema by elevation of intraocular pressure. Ann. Ophthalmol, 1984; 16: 890–894.
• Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch. Ophthalmol, 1966; 76: 477–483.
• Jonas JB, Harder B, Kamppeter B. Inter- eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol, 2004; 138(6): 970-977
• Jonas J, Kreissıg I, Degenrıng R. Complication of infectious and sterile endophthalmitis triamcinolone acetonide. Br. J. Ophthalmol, 2004; 88: 92-95
• Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis triamcinolone acetonide injection. Retina, 2003; 23: 686–691.
• Rodney SB, Edward H. Effect of intravitreal triamcinolone acetodine on suspectibility into experimental bacterial endophthalmitis and subsequent respondse to treatment. Arch Ophthalol, 2005; 123: 649- 653
• Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment exudative and neovascular disease. Progress in Retinal and Eye Research, 2005; 24: 587- 611
• Çekiç O, Chang S, Tseng JJ, et al.Cataract progression after intravitreal triamcinolone injection. Am. J. Ophthalmol, 2005; 139:993-998 A.
• Intravitreal pressure elevation after after intravitreal after intravitreal of intraocular proliferative, 51-Chen SD
• Lochhead J, McDonald B., et al. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br. J. Ophthalmol, 2004; 88: 843–844. 52-Sutter
• triamcinolone for radiation-induced macular edema. Arch. Ophthalmol, 2003; 121: 1491– 1493.
• Jaissle GB, Szurman P, Bartz-Schmidt KU. Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid- Therapie. Ophthalmologe, 2004; 101: 121–128.
• Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol, 2001; 29: 2–6.
• Degenring RF, Jonas JB. Rinsing ofthe cannula prior to intravitreal injection. Arch. Ophthalmol, 2004; 122: 1571–1572 .
• Yeung CK, Chan KP, Chan CK, et al. Cytotoxicity oftriamcinolon e on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn. J. Ophthalmol, 2004; 48: 236–242. Dr.